SituGen: Device to revolutionize extraction of cord stem cells
Impact, a medical device startup, has developed a revolutionary system for extracting blood rich with stem cells from umbilical cords.
The device, called the SituGen, is a sophisticated mechanism which enables up to twice the amount of blood to be extracted compared with the needle method now in use worldwide.
Impact is a research and development company – a sister company of BioCord, an Israeli private cord blood bank operating in Israel.
The major problem of cord blood banking by private and public banks is the limited amount of blood extracted by using the needle technique by gravitation into a standard blood collecting bag. This small amount enables transplant only to 45 kg worth of body weight and therefore not to adults, according to the company.
The patent-pending SituGen is a disposable kit for cord blood stem cell (CBSC) collection.
Impact and BioCord CEO Miki Shacham says stem cells extraction from umbilical cords is growing at a phenomenal 45 percent annual rate worldwide, with the US the leader in the practice.
According to Shacham, awareness is growing of the benefits of banking cord blood stem cells, which can treat up to 80 diseases. He predicted that the US would be the top market for the product.
Manufacturing plans have already been prepared for the SituGen and it is expected to be ready for market by the end of the year.
The company is seeking an investor to bring the product to market and complete the FDA and CE approval process.
The development of the product was launched with the support of the Office of the Chief Scientist.
The scientific board of the company includes Prof. Joseph Itzkoviz, who was a member of the team that was the first in the world to isolate embryonic stem cells.